

# Cost-Effectiveness of Certolizumab Pegol for the Treatment of Axial Spondyloarthritis in Turkey

Çağlayan B,<sup>1</sup> Firdin A,<sup>1</sup> Sarıca N,<sup>1</sup> Tatar M,<sup>2</sup> Eşsiz M<sup>3</sup>

<sup>1</sup>UCB Pharma, Istanbul, Turkey; <sup>2</sup>Hacettepe Universtiy, Ankara, Turkey; <sup>3</sup>Polar Sağlık Health Economics & Policy, Ankara, Turkey

#

## OBJECTIVES

- The objective of this study was to assess the cost-effectiveness of CZP in axSpA patients in Turkey compared to other anti-TNFs and standard of care.

## BACKGROUND

- Axial spondyloarthritis (axSpA) is a rheumatic disease that includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).
- Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF, indicated for the treatment of axSpA.

## METHODS

- A Markov model was developed to estimate costs and outcomes associated with CZP and comparator treatment.
- The study was undertaken from the Turkish healthcare payer perspective.
- The primary endpoint was ASAS20 response.
- A mixed treatment comparison was undertaken to compare CZP with adalimumab, infliximab, etanercept and golimumab for the treatment of AS.
- Similar comparisons were made for the treatment of nr-axSpA, where CZP was compared with adalimumab.
- Costs and effects were evaluated over a lifetime and discounted at 3%.
- Results were presented as incremental cost/life years gained.
- One-way and probabilistic sensitivity analyses were also conducted.

Table 1. ICERs for AS treatment comparing CZP to other anti-TNFs and standard of care (12 weeks)

	ADA	IFX	ETA	GOL	Standard of care
Incremental cost (Turkish Lira)	-22.436,56	-48.336,84	-18.459,82	-22.020,83	47.843,76
Life years gained	0.000	0.000	0.000	0.000	0.000
ICER	Cheaper, equally effective	Cheaper, equally effective	Cheaper, equally effective	Cheaper, equally effective	Dominated

ADA: Adalimumab; ICER: Incremental cost-effectiveness ratio; IFX: Infliximab; ETA: Etanercept; GOL: Golimumab

Table 2. ICERs for AS treatment comparing CZP to other anti-TNFs and standard of care (24 weeks)

	ADA	IFX	ETA	GOL	Standard of care
Incremental cost (Turkish Lira)	-4.955,72	-41.599,72	-5.150,75	-5.022,52	56.346,04
Life years gained	0.000	0.000	0.000	0.000	0.000
ICER	Cheaper, equally effective	Cheaper, equally effective	Cheaper, equally effective	Cheaper, equally effective	Dominated


ADA: Adalimumab; ICER: Incremental cost-effectiveness ratio; IFX: Infliximab; ETA: Etanercept; GOL: Golimumab

Table 3. ICERs for nr-axSpA treatment comparing CZP to other anti-TNFs and standard of care

	ADA	Standard of care
Incremental cost (Turkish Lira)	-2.396,26	48.187,94
Life years gained	0.000	0.000
ICER	Dominant	Dominated

ADA: Adalimumab; ICER: Incremental cost-effectiveness ratio

Figure 1. Model diagram



## Model Inputs

- Resource utilization data were obtained from expert clinical opinion, including physician visits, monitoring costs, and others.
- Unit costs were taken from the Social Security Institution's 2015 official price list.

## RESULTS

- The base case analysis for AS showed that CZP was equally effective and less costly compared to adalimumab, infliximab, etanercept and golimumab.
- In nr-axSpA, CZP dominated adalimumab. Sensitivity analyses confirmed the robustness of the model.

## CONCLUSIONS

- The present analyses showed that CZP is a cost-effective alternative therapy for the treatment axSpA patients in Turkey.

## References

1. Placeholder

## Acknowledgements

This study was funded by UCB Pharma. Editorial services for this poster were provided by Costello Medical Consulting. All costs associated with development of this poster were funded by UCB Pharma.